Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials. (2024). SKIN The Journal of Cutaneous Medicine, 8(2), s366. https://doi.org/10.25251/skin.8.supp.366